Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.AFFiRiS has reported the results of the preclinical development of its first Parkinson's vaccine PD01. The Parkinson's vaccine specifically acts against a protein known as alpha-synuclein (alpha-syn) which strongly contributes to the clinical profile of Parkinson's disease.
Subscribe to our email newsletter
AFFiRiS said that the vaccine has undergone numerous preclinical tests which have confirmed its principle of action (Proof of Concept). The company is now starting to prepare for clinical trials of the vaccine which are planned to commence at the beginning of 2011.
The basis of PD01 is the company’s Affitom technology, on which two vaccines for Alzheimer’s disease are based that have already successfully completed their initial clinical studies.
Walter Schmidt, director and co-founder at AFFiRiS, said: “We have had PD01 evaluated in various preclinical systems. All the tests have shown that this vaccine works against alpha-syn. In addition to histological and biochemical analyses, we have even been able to observe behavioural improvements as a result of our vaccination. We are now starting preparations for the clinical trial of PD01 which will supplement our current clinical programmes.”
Frank Mattner, CSO at AFFiRiS, said: “Our Affitom technology allows us to develop vaccines that guarantee this high level of specificity to alpha-syn. During 2010 we will complete the preliminary work for the clinical trial.”